Lipigon acquires antisense drug candidates for cardiovascular and metabolic diseases from Secarna

Updated: May 14

“We are very pleased with the Secarna collaboration under the target validation agreement. Together we have built a strong patent portfolio and moreover, we have generated a powerful in vivo and in vitro data package. Secarna’s impressive LNAplusTM platform has given us fully optimized clinical candidates that we are looking forward to bringing into IND-enabling studies.” says CEO and co-founder Stefan K. Nilsson. “The acquisition is in line with Lipigon’s business model to fully control our pipeline until out-licensing or market introduction. We believe that this agreement will make our case more attractive for investors”.


Read full press release below.

PR Lipigon Secarna March 23rd 2020
.pdf
Download PDF • 139KB